J&J Targets Tremfya Growth In PsA
Positive Data Presented At ACR
The healthcare giant is looking for a second approval for its IL-23 blocker and tells Scrip the results from the DISCOVER program show that the drug can make its mark in psoriatic arthritis as well as psoriasis.
